Acute biphenotypic leukemia arising in a patient with essential thrombocythemia

American Journal of Hematology

Volumn 81, Issue 8, 2006, Pages 624-626

  Wong, Gee Chuan ^a   Lee, Lai Heng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Acute biphenotypic leukemia; Anagrelide; Essential thrombocythemia; Hydroxyurea; Interferon; Transformation

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; HYDROXYUREA; IDARUBICIN; INTERFERON; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; ARTICLE; BACTERIAL PNEUMONIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTHEMIA; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 20; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; LEUKEMIA; MIDDLE AGED; QUINAZOLINES; REMISSION INDUCTION; THROMBOCYTHEMIA, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 33745990476     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20651     Document Type: Article

References (21)

1. Shibata K, Shimamoto Y, Suga K. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta Haematol 1994; 91:84-88.
2. Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982;77:353-356.
3. Emilia G, Sacchi S, Temperani P. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. Leuk Lymphoma 1993;9:423-426.
4. Michels JJ. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. Hematol J 2004;5(2):92-102.
5. Bene MC, Castoldi G, Knapp W. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9(10):1783-1786.
6. Bene MC, Bernier M, Casasnovas RO. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998;92(2): 596-599.
7. Razzan M, Tamponi G, Schinco P. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999;78:539-543.
8. Sterkers Y, Preudhomme C, Lai JL. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
9. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392.
10. Radaelli F, Mazza R, Curioni E. Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002;69(2):108-111.
11. Martin SE, DellaValla J. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant. Leukemia 2005;19(6):1095-1096.
12. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000;37:379-385.
13. Harrison CN, Campbell PJ, Wheatley K. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
14. Barbui T, Barosi G, Grossi A. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232.
15. Gugliotta L, Marchiolo R, Fiacchini M. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythaemia in a retrospective study of the GIMMC group in two thousand patients. Blood 1997;90:348a, abstract > 1523.
16. Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997;78:622-626.
17. Fruchtman SM, Petitt RM, Gilbert HS. Anagrelide Study Group: Anagrelide: Analysis of long term safety and leukemogenic potential in myeloproliferative diseases. Leuk Res 2005;29:481-491.
18. Storen EC, Tefferi A. long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866.
19. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004; 41(suppl 3):15-17.
20. Kreft A, Burg J, Fischer T. Essential thrombocythemia terminating in pure erythroleukemia. Am J Hematol 2004;77(2):140-143.
21. Kim J, Park CJ, Seo EJ. A case of biphenotypic blast crisis of unclassified myeloproliferative disorder. Ann Hematol 2002;8(10):603-604.